)
)
)
InnoPath Therapeutics
ABOUT INNOPATH
InnoPath Therapeutics is a pre-clinical-stage dermatologic oncology company developing next-generation topical treatments for actinic keratosis (AK) and non-melanoma skin cancer (NMSC)—conditions affecting tens of millions of patients each year and often treated today with therapies that cause significant pain, inflammation, and poor adherence. InnoPath’s approach is to reformulate well-characterized active molecules into precision topicals designed to selectively target diseased cells while minimizing damage to healthy skin, aiming to deliver strong efficacy with a far better patient experience. By leveraging an efficient 505(b)(2) regulatory pathway and a growing intellectual property portfolio around formulation, method of use, and novel applications, the company is pursuing a faster, lower-risk path to market while addressing one of the largest unmet needs in dermatology.
What is your next catalyst (value inflection) update?
We are closing our seed round and working on a 25M series A that will begin later this summer.
Year Founded
2024
Lead Product in Development
We have completed a non clinical POC study on the class of drugs and will carry three into a comparative non clinical study to determine which has the best efficacy profile. All candidates will outperform the current standard of care when it comes to the side effect profile and overall safety.
Development Phase of Lead Product
Pre-Clinical
CEO/Top Company Official
Peter Trepp
When you expect your next catalyst update?
August 2026
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
